Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 62 clinical trials
Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer

RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy, such as cyproterone acetate may stop the adrenal glands from making androgens. Sometimes the tumor may not need treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether giving cyproterone acetate …

hormone therapy
androgens
epinephrine
gonadorelin
gonadotropin
  • 3 views
  • 07 Nov, 2020
  • 1 location
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. PURPOSE: This randomized phase III trial is studying how well androgen deprivation therapy works in treating patients with prostate cancer.

androgen suppression
antiandrogen therapy
androgens
epinephrine
antiandrogens
  • 401 views
  • 07 Nov, 2020
  • 9 locations
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I Stage II or Stage III HER2-Positive Breast Cancer

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. …

epirubicin
stage iii breast cancer
HER2
tumor cells
tamoxifen
  • 33 views
  • 07 Nov, 2020
  • 1 location
Recombinant LH Prior to Ovarian Stimulation in Poor Ovarian Responders (PRE-LH)

described and oocyte donation is often offered as their only option to achieve pregnancy. Recently, evidence has emerged that supplementation with a specific hormone, luteinizing hormone (LH

antral
luteinizing hormone
ovarian stimulation
antral follicle count
body mass index
  • 0 views
  • 24 Jan, 2021
  • 3 locations
Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer

The present investigation aims to evaluate the efficacy of an innovative protocol of controlled ovarian stimulation for breast cancer patients, who are candidates for fertility preservation. Currently, vitrification of oocytes and/or embryos after controlled ovarian stimulation is the most established method for female fertility preservation. However, this stimulation induces an …

follicle stimulating hormone
cancer
ductal carcinoma
estrogen
breast cancer
  • 0 views
  • 26 Apr, 2021
  • 1 location
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as

  • 0 views
  • 15 Jun, 2021
  • 99 locations
Prolonged Protocol of Early Follicular or Mid Luteal Phase

advantages in achieving ideal egg number, increasing endometrial receptivity to embryo transfer, inhibiting endogenous luteinizing hormone (LH) peak and reducing cycle cancellation rate. The full dose of

antral
gonadotropin
antral follicle count
ovarian hyperstimulation
controlled ovarian hyperstimulation
  • 5 views
  • 24 Jan, 2021
  • 1 location
Prostate Adenocarcinoma TransCutaneous Hormones

investigation of the treatment in this setting, as recommended by the IDMC.. PURPOSE: This randomized phase III trial is studying how well the estrogen skin patch works compared with luteinizing hormone

androgen suppression
antiandrogen therapy
estrogen
prostate cancer metastatic
estradiol
  • 291 views
  • 27 Jan, 2021
  • 2 locations
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

modulator (such as tamoxifen) or an aromatase inhibitor (anastrozole, letrozole, exemestane) or fulvestrant (Faslodex). Premenopausal women and men may also receive a drug called an LHRH (luteinizing

gnrh
hormone therapy
exemestane
estrogen
letrozole
  • 0 views
  • 24 May, 2021
  • 69 locations
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer (ABC)

epidermal growth factor
erbb2
letrozole
fulvestrant
HER2
  • 63 views
  • 27 Jan, 2021
  • 67 locations